Everest Medicines Limited (HKG:1952)
Hong Kong · Delayed Price · Currency is HKD 39.20
+0.96 (2.51%)
Feb 13, 2026, 4:08 PM HKT
Everest Medicines Market Cap
Everest Medicines has a market cap or net worth of 13.51 billion as of February 13, 2026. Its market cap has increased by 10.80% in one year.
Market Cap
13.51B
Enterprise Value
12.58B
Revenue
932.82M
Ranking
n/a
PE Ratio
n/a
Stock Price
39.20
Market Cap Chart
Since October 9, 2020, Everest Medicines's market cap has decreased from 20.64B to 13.51B, a decrease of -34.54%. That is a compound annual growth rate of -7.61%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 13, 2026 | 13.85B | 6.00% |
| Dec 31, 2025 | 13.06B | -16.21% |
| Dec 31, 2024 | 15.59B | 132.87% |
| Dec 29, 2023 | 6.70B | 24.60% |
| Dec 30, 2022 | 5.37B | -47.96% |
| Dec 31, 2021 | 10.33B | -47.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Oct 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Ascletis Pharma | 17.87B |
| Ascentage Pharma Group International | 17.53B |
| Zai Lab | 16.67B |
| Keymed Biosciences | 16.42B |
| Guangzhou Innogen Pharmaceutical Group | 12.62B |
| Nanjing Leads Biolabs | 12.01B |
| Shanghai Haohai Biological Technology | 10.94B |
| HBM Holdings | 9.79B |